NHS could claw back £502m if Lyrica ruling upheld, study finds
The NHS could reclaim up to £502 million in excess prescribing costs relating to Pfizer’s pregabalin if the drug giant’s last effort to uphold the drug’s legal protection is unsuccessful, a study has found.
Read More
